NASDAQ:VERV Verve Therapeutics (VERV) Stock Price, News & Analysis → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free VERV Stock Alerts $6.20 -0.21 (-3.28%) (As of 11:09 AM ET) Add Compare Share Share Today's Range$6.11▼$6.4650-Day Range$6.00▼$17.9652-Week Range$5.84▼$21.42Volume210,698 shsAverage Volume1.21 million shsMarket Capitalization$520.30 millionP/E RatioN/ADividend YieldN/APrice Target$33.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Verve Therapeutics alerts: Email Address Verve Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside414.8% Upside$33.00 Price TargetShort InterestBearish28.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.31Based on 5 Articles This WeekInsider TradingSelling Shares$12,475 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.92) to ($2.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector464th out of 908 stocksPharmaceutical Preparations Industry205th out of 424 stocks 3.4 Analyst's Opinion Consensus RatingVerve Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageVerve Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.64% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Verve Therapeutics has recently increased by 2.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERV. Previous Next 2.1 News and Social Media Coverage News SentimentVerve Therapeutics has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Verve Therapeutics this week, compared to 3 articles on an average week.Search Interest9 people have searched for VERV on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows10 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,475.00 in company stock.Percentage Held by Insiders21.40% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Verve Therapeutics are expected to grow in the coming year, from ($2.92) to ($2.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Verve Therapeutics Stock (NASDAQ:VERV)Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More VERV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERV Stock News HeadlinesMay 7, 2024 | finance.yahoo.comVerve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102May 5, 2024 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Trading 7.8% Higher May 7, 2024 | DTI (Ad)The best inflation-proof investment The markets are CRAZY right now. Which is why thousands of investors are flocking into one little-known company. May 3, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Reaches New 12-Month Low at $5.93April 27, 2024 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Reaches New 1-Year Low at $6.05April 18, 2024 | wsj.comGV’s Newest Life Sciences General Partner Pursues Precision TreatmentsApril 18, 2024 | msn.comVerve Therapeutics (VERV) Price Target Decreased by 37.88% to 32.77May 7, 2024 | DTI (Ad)The best inflation-proof investment The markets are CRAZY right now. Which is why thousands of investors are flocking into one little-known company. April 11, 2024 | benzinga.comTop 3 Health Care Stocks Which Could Rescue Your Portfolio This QuarterApril 9, 2024 | markets.businessinsider.comBuy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated RecoveryApril 9, 2024 | msn.comA Bold Gene-Editing Solution Began Testing—Then Hit the Strangest TwistApril 6, 2024 | fool.comAfter a Serious Setback, Is Verve Therapeutics a Buy?April 3, 2024 | msn.comGene Editing Experiment Halted as Patient Gets Weird Side EffectsApril 3, 2024 | seekingalpha.comVerve Therapeutics: An Update On Human CRISPRApril 3, 2024 | seekingalpha.comVerve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment PauseApril 2, 2024 | msn.comVerve Therapeutics pauses enrollment of patients in trial for its gene therapy to treat high cholesterol after severe side effectApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics with Strategic Focus on Promising VERVE-102 ProgramApril 2, 2024 | bizjournals.comVerve’s stock tumbles as biotech pauses gene editing trial over safety concernsApril 2, 2024 | marketwatch.comVerve Therapeutics Pauses Enrollment in Trial of Gene Editing Medicine After Serious Adverse EventApril 2, 2024 | markets.businessinsider.comVerve Therapeutics To Halt Enrollment In Heart-1 Phase 1b Trial Of VERVE-101; Stock FallsApril 2, 2024 | msn.comVerve drops after pausing enrollments in trial for lead assetApril 2, 2024 | msn.comVerve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setbackApril 2, 2024 | finance.yahoo.comVerve Falls as Gene-Editing Trial Paused on Safety IssuesApril 2, 2024 | finance.yahoo.comVerve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side EffectsApril 2, 2024 | reuters.comVerve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levelsApril 2, 2024 | globenewswire.comVerve Therapeutics Announces Updates on its PCSK9 ProgramSee More Headlines Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/07/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VERV CUSIPN/A CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees255Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$55.00 Low Stock Price Target$15.00 Potential Upside/Downside+414.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-200,070,000.00 Net Margins-1,701.70% Pretax Margin-1,699.21% Return on Equity-39.33% Return on Assets-30.92% Debt Debt-to-Equity RatioN/A Current Ratio17.24 Quick Ratio17.24 Sales & Book Value Annual Sales$11.76 million Price / Sales45.75 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book0.88Miscellaneous Outstanding Shares83,923,000Free Float65,963,000Market Cap$537.95 million OptionableOptionable Beta1.94 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Burt A. Adelman M.D. (Age 72)Co-Founder & Independent Chairman of the Board Comp: $87.55kDr. Sekar Kathiresan M.D. (Age 52)Co-Founder, CEO & Director Comp: $899.55kMr. Andrew D. Ashe J.D. (Age 57)President, COO & General Counsel Comp: $703.85kDr. Andrew Bellinger M.D. (Age 45)Ph.D., Chief Scientific Officer Comp: $703.85kDr. Kiran Musunuru M.D.M.P.H., Ph.D., Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Anthony Philippakis M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Co-Founder Mr. Issi Rozen M.B.A.Co-Founder & Strategic AdvisorMs. Allison Dorval (Age 48)CFO & Principal Accounting Officer Comp: $260.93kMore ExecutivesKey CompetitorsAstria TherapeuticsNASDAQ:ATXSApplied TherapeuticsNASDAQ:APLTShattuck LabsNASDAQ:STTKAdlai NortyeNASDAQ:ANLArbutus BiopharmaNASDAQ:ABUSView All CompetitorsInsiders & InstitutionsNikko Asset Management Americas Inc.Bought 194,594 shares on 5/3/2024Ownership: 3.089%Mirae Asset Global Investments Co. Ltd.Bought 59,034 shares on 5/1/2024Ownership: 0.205%China Universal Asset Management Co. Ltd.Bought 7,256 shares on 4/29/2024Ownership: 0.019%Sumitomo Mitsui Trust Holdings Inc.Bought 194,594 shares on 4/19/2024Ownership: 3.100%Green Alpha Advisors LLCBought 2,574 shares on 4/10/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions VERV Stock Analysis - Frequently Asked Questions Should I buy or sell Verve Therapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERV shares. View VERV analyst ratings or view top-rated stocks. What is Verve Therapeutics' stock price target for 2024? 8 analysts have issued twelve-month price objectives for Verve Therapeutics' stock. Their VERV share price targets range from $15.00 to $55.00. On average, they expect the company's stock price to reach $33.00 in the next year. This suggests a possible upside of 414.8% from the stock's current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts. How have VERV shares performed in 2024? Verve Therapeutics' stock was trading at $13.94 at the beginning of 2024. Since then, VERV shares have decreased by 54.0% and is now trading at $6.41. View the best growth stocks for 2024 here. When is Verve Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VERV earnings forecast. How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) posted its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.14. The firm had revenue of $5.14 million for the quarter, compared to the consensus estimate of $3.95 million. Verve Therapeutics had a negative net margin of 1,701.70% and a negative trailing twelve-month return on equity of 39.33%. What ETFs hold Verve Therapeutics' stock? ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Direxion Moonshot Innovators ETF (MOON), Global X Genomics & Biotechnology ETF (GNOM), Tema Cardiovascular and Metabolics ETF (HRTS), AXS Green Alpha ETF (NXTE).ARK Innovation ETF (ARKK) and When did Verve Therapeutics IPO? Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO. Who are Verve Therapeutics' major shareholders? Verve Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (3.10%), Nikko Asset Management Americas Inc. (3.09%), Mirae Asset Global Investments Co. Ltd. (0.20%), Green Alpha Advisors LLC (0.03%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Joan Nickerson, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan. View institutional ownership trends. How do I buy shares of Verve Therapeutics? Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERV) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyDave Ramsey Shocks Millions With US Dollar LunacyAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldBiden’s Sneaky H.R. 5376 Is A Nightmare For Retirement SaversBirch GoldIs Tesla going out of business?DTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
